Devarbhavi, 2021 - Google Patents
Drug‐induced liver injury unique to IndiaDevarbhavi, 2021
View PDF- Document ID
- 16686592927094012377
- Author
- Devarbhavi H
- Publication year
- Publication venue
- Clinical Liver Disease
External Links
Snippet
Drugâ•’Induced Liver Injury Unique to India Page 1 108 |CliniCal liver Disease, vOl 18, nO 3,
sePTeMBer 2021 An Official Learning Resource of AASLD review Drug- induced liver injury
Unique to india Harshad Devarbhavi, MD, DM The drugs causing drug- induced liver injury (DILI) …
- 206010072268 Drug-induced liver injury 0 title abstract description 41
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Devarbhavi | Drug‐induced liver injury unique to India | |
| RECOVERY Collaborative Group | Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | |
| Wolff et al. | Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis | |
| Scott et al. | Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? | |
| Hammer et al. | Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel | |
| Booth et al. | Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS) | |
| Devarbhavi | Antituberculous drug-induced liver injury: current perspective | |
| Stern et al. | A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients | |
| Dominick et al. | HIV-related cardiovascular diseases: the search for a unifying hypothesis | |
| Filler et al. | Four‐year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion | |
| Koklu et al. | Differences in nephrotoxicity risk and renal effects among anti‐viral therapies against hepatitis B | |
| Devarbhavi et al. | Drug‐induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis | |
| Ortiz et al. | Drug-induced liver injury and COVID-19: A review for clinical practice | |
| Mankhatitham et al. | Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen | |
| Bredemeier et al. | Safety of the methotrexate–leflunomide combination in rheumatoid arthritis: Results of a multicentric, registry-based, cohort study (BiobadaBrasil) | |
| Lopez‐Solis et al. | Gastrointestinal side effects in liver transplant recipients taking enteric‐coated mycophenolate sodium vs. mycophenolate mofetil | |
| Heil et al. | Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients | |
| Yosofi et al. | Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and meta-analysis | |
| Lee et al. | Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg‐positive cancer patients undergoing chemotherapy | |
| Shin et al. | Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center | |
| Shibbiru et al. | Adverse drug reactions: An overview | |
| Silva et al. | Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation | |
| Renzulli et al. | Pancreas divisum inversus | |
| Kadhiravan et al. | Medical management of genitourinary tuberculosis | |
| Ayoub et al. | Hepatic safety and tolerability in the maraviroc clinical development program |